PRESTRELSKI STEVEN (Chief Scientific Officer) received a stock award from XERIS BIOPHARMA HOLDINGS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/5/2022ACC: 0001867096-22-000006
Officer· Chief Scientific Officer
Since Oct 2021
+75K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
75K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+75K
Price / share
—
Trade value
—
% of position
15.2%
1/3/2022
494.78K→569.78K
Total
Net shares
+75K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/3/2022 | A · Award | +75K | — | — | 15.2% | 494.78K | 569.78K |
| Total | +75K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported